Movement Alert｜Ionis Pharmaceuticals Falls 5.01% in Regular Trading, Cardiovascular Pipeline Setbacks and Analyst Target Cuts Weigh on Shares

Market Focus09-19

On September 19, Ionis Pharmaceuticals fell 5.01% in regular trading, trading at $44.41/share, with turnover of $1.49 billion, extending a prolonged downtrend.

The decline reflects continued fallout from back-to-back failures in the company's cardiovascular pipeline. On September 8, pelacarsen, co-developed with Novartis for cardiovascular disease, failed to meet its primary endpoint in a late-stage trial, triggering a 13% pre-market plunge. Earlier in July, Eplontersen, partnered with AstraZeneca for transthyretin-mediated amyloid cardiomyopathy, also failed its Phase 3 primary efficacy endpoint, causing shares to drop over 20% in a single session. These consecutive setbacks have severely eroded investor confidence in the company's core R&D capabilities.

Adding to the pressure, Bank of America cut its price target from $93 to $91, while TD Cowen lowered its target from $108 to $94, reflecting deteriorating institutional sentiment. The stock has fallen sharply from levels above $80 earlier this year despite positive developments including FDA approval of Zanvastro for Alexander disease and strong Q1 revenue of $246 million that beat estimates.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1194024119?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-19 03:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194024119","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Ionis Pharmaceuticals Falls 5.01% in Regular Trading, Cardiovascular Pipeline Setbacks and Analyst Target Cuts Weigh on Shares","media":"Market Focus","content":"<p><p>On September 19, Ionis Pharmaceuticals fell 5.01% in regular trading, trading at $44.41/share, with turnover of $1.49 billion, extending a prolonged downtrend.</p><p>The decline reflects continued fallout from back-to-back failures in the company's cardiovascular pipeline. On September 8, pelacarsen, co-developed with Novartis for cardiovascular disease, failed to meet its primary endpoint in a late-stage trial, triggering a 13% pre-market plunge. Earlier in July, Eplontersen, partnered with AstraZeneca for transthyretin-mediated amyloid cardiomyopathy, also failed its Phase 3 primary efficacy endpoint, causing shares to drop over 20% in a single session. These consecutive setbacks have severely eroded investor confidence in the company's core R&D capabilities.</p><p>Adding to the pressure, Bank of America cut its price target from $93 to $91, while TD Cowen lowered its target from $108 to $94, reflecting deteriorating institutional sentiment. The stock has fallen sharply from levels above $80 earlier this year despite positive developments including FDA approval of Zanvastro for Alexander disease and strong Q1 revenue of $246 million that beat estimates.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Ionis Pharmaceuticals Falls 5.01% in Regular Trading, Cardiovascular Pipeline Setbacks and Analyst Target Cuts Weigh on Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Ionis Pharmaceuticals Falls 5.01% in Regular Trading, Cardiovascular Pipeline Setbacks and Analyst Target Cuts Weigh on Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-19 03:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 19, Ionis Pharmaceuticals fell 5.01% in regular trading, trading at $44.41/share, with turnover of $1.49 billion, extending a prolonged downtrend.</p><p>The decline reflects continued fallout from back-to-back failures in the company's cardiovascular pipeline. On September 8, pelacarsen, co-developed with Novartis for cardiovascular disease, failed to meet its primary endpoint in a late-stage trial, triggering a 13% pre-market plunge. Earlier in July, Eplontersen, partnered with AstraZeneca for transthyretin-mediated amyloid cardiomyopathy, also failed its Phase 3 primary efficacy endpoint, causing shares to drop over 20% in a single session. These consecutive setbacks have severely eroded investor confidence in the company's core R&D capabilities.</p><p>Adding to the pressure, Bank of America cut its price target from $93 to $91, while TD Cowen lowered its target from $108 to $94, reflecting deteriorating institutional sentiment. The stock has fallen sharply from levels above $80 earlier this year despite positive developments including FDA approval of Zanvastro for Alexander disease and strong Q1 revenue of $246 million that beat estimates.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IONS","symbol_name":"Ionis Pharmaceuticals, Inc","start_time":0,"source_url":"","article_id":"1194024119","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194024119","pubTimestamp":1789761595,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 19, Ionis Pharmaceuticals fell 5.01% in regular trading, trading at $44.41/share, with turnover of $1.49 billion, extending a prolonged downtrend.The decline reflects continued fallout...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IONS":"Ionis Pharmaceuticals, Inc"},"translate_title":"走势警报|Ionis Pharmaceuticals 常规交易中下跌 5.01%，心血管管道受挫和分析师目标下调令股价承压","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IONS":1},"content_text":"On September 19, Ionis Pharmaceuticals fell 5.01% in regular trading, trading at $44.41/share, with turnover of $1.49 billion, extending a prolonged downtrend.The decline reflects continued fallout from back-to-back failures in the company's cardiovascular pipeline. On September 8, pelacarsen, co-developed with Novartis for cardiovascular disease, failed to meet its primary endpoint in a late-stage trial, triggering a 13% pre-market plunge. Earlier in July, Eplontersen, partnered with AstraZeneca for transthyretin-mediated amyloid cardiomyopathy, also failed its Phase 3 primary efficacy endpoint, causing shares to drop over 20% in a single session. These consecutive setbacks have severely eroded investor confidence in the company's core R&D capabilities.Adding to the pressure, Bank of America cut its price target from $93 to $91, while TD Cowen lowered its target from $108 to $94, reflecting deteriorating institutional sentiment. The stock has fallen sharply from levels above $80 earlier this year despite positive developments including FDA approval of Zanvastro for Alexander disease and strong Q1 revenue of $246 million that beat estimates.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1194024119","isCrawlerRequest":true}